Management of Retinal Detachment in a Prediabetic Patient

Immediate Management

The American Diabetes Association recommends urgent ophthalmology referral for patients with retinal detachment, regardless of whether they have frank diabetes or only prediabetes, as retinal detachment represents a vision-threatening emergency that demands urgent specialist management 1, 2
The presence of retinal detachment suggests advanced proliferative changes with vitreoretinal traction, which can occur even in prediabetic states with chronic hyperglycemia, according to the American Academy of Ophthalmology 3, 4

B-scan ultrasonography should be performed to assess the extent of vitreoretinal traction, quantify any vitreous hemorrhage, and fully characterize the retinal detachment when media opacity limits direct visualization, as recommended by the American Academy of Ophthalmology 5
Optical coherence tomography (OCT) provides high-resolution imaging of the vitreoretinal interface and can demonstrate attached posterior hyaloid and macular involvement, according to the American Academy of Ophthalmology 6

Pars plana vitrectomy is the definitive treatment for diabetic retinal detachment with vitreoretinal traction, as recommended by the American Academy of Ophthalmology 1, 7
The procedure involves removal of the thickened posterior hyaloid using aspiration, illuminated pick, or forceps to relieve tangential traction at the macula, according to the American Society of Retina Specialists 6

The American Diabetes Association recommends optimizing blood glucose control to near-normoglycemia to prevent further retinopathy progression, even though the patient currently has only prediabetes 2, 3, 4
The American Heart Association recommends optimizing blood pressure and serum lipid control as these are modifiable risk factors that influence retinopathy progression 2, 3, 4

Serial OCT imaging every 1-2 months is recommended to monitor for macular edema resolution and anatomic stability, according to the American Academy of Ophthalmology 6
Panretinal photocoagulation (PRP) or anti-VEGF therapy should be considered to address the underlying proliferative diabetic retinopathy that caused the detachment, as recommended by the American Academy of Ophthalmology 2, 7, 4
Intravitreal anti-VEGF injections (ranibizumab) are non-inferior to PRP for proliferative diabetic retinopathy, though they require reliable patient follow-up, according to the American Academy of Ophthalmology 2, 7, 4